Evidence map›Paper›PMID 35225886›Full record

ArticleNeurology international2022

Serum CGRP Changes following Ultrasound-Guided Bilateral Greater-Occipital-Nerve Block.

Abdelrahman Abbas, Ramez Moustafa, Ali Shalash, Mahmoud Haroun, Randa Amin, Sherien Borham, Ahmed Elsadek, Shahinaz Helmy

Open access · goldAbstract read
In one paragraph

Article in Neurology international, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 14 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Greater Occipital Nerve Block as Preventive Treatment in Migraine: A Time-To-Event Analysis.Pain practice : the official journal of World Institute of Pain · 2025
    Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Abdelrahman AbbasDepartment of Neurology, Faculty of Medicine, Ain Shams University, 12th Abbassiya Street, Cairo 08080, Egypt.ORCID 0000-0001-7089-647X
Ramez MoustafaDepartment of Neurology, Faculty of Medicine, Ain Shams University, 12th Abbassiya Street, Cairo 08080, Egypt.
Ali ShalashDepartment of Neurology, Faculty of Medicine, Ain Shams University, 12th Abbassiya Street, Cairo 08080, Egypt.ORCID 0000-0001-7012-5907
Mahmoud HarounDepartment of Neurology, Faculty of Medicine, Ain Shams University, 12th Abbassiya Street, Cairo 08080, Egypt.
Randa AminDepartment of Neurology, Faculty of Medicine, Ain Shams University, 12th Abbassiya Street, Cairo 08080, Egypt.
Sherien BorhamDepartment of Neurology, Faculty of Medicine, Ain Shams University, 12th Abbassiya Street, Cairo 08080, Egypt.
Ahmed ElsadekDepartment of Neurology, Faculty of Medicine, Ain Shams University, 12th Abbassiya Street, Cairo 08080, Egypt.
Shahinaz HelmyDepartment of Neurology, Faculty of Medicine, Ain Shams University, 12th Abbassiya Street, Cairo 08080, Egypt.
Ain Shams University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Calcitonin-gene-related peptide (CGRP) and CGRP receptors are expressed in trigeminal nerve cells, and treatments targeting CGRP are effective in migraines. For headaches that do not respond to pharmacological treatment, minimally invasive techniques such as greater-occipital-nerve block (GONB) can help relieve the pain and reduce the frequency of headaches. Our study assessed the efficacy of ultrasound-guided greater-occipital-nerve block (USgGONB) in chronic migraines (CM) and its relationship to serum CGRP levels. Methods: Forty chronic migraineurs who underwent bilateral USgGONB using 40 mg triamcinolone and 1 mL lidocaine were recruited and interictal serum CGRP samples were collected immediately before and one month after GONB. The clinical response was evaluated using headache diaries before and one month after USgGONB. The patient response was determined after USgGONB according to the reduction in headache days as a good responder (>50% reduction), poor responder (<50%) or non-responder. Results: Monthly headache days after GONB showed a significant reduction (median, 10 days; range, 8−14.7) compared to before the block (median, 18 days; range, 17−22; p < 0.001). Across all patients, interictal serum CGRP levels after USgGONB were significantly lower than before the block (median, 40 pg/mL (range, 25−60) vs. 145 pg/mL (range, 60−380) (p = 0.001). The pre-treatment interictal CGRP levels showed a significant difference (p = 0.003), as their levels in non-responders (median, 310 pg/mL; interquartile range, 262−350) were significantly higher than those seen in responders, whether poor responders (median, 135 pg/mL; interquartile range, 100−200 pg/mL) or good responders (median, 140 pg/mL; interquartile range, 80−150 pg/mL). Conclusion: the study showed the beneficial effect of USgGONB in chronic migraines that was associated with lowering interictal CGRP levels, implying a potential role for CGRP in the mechanism of action of GONB in CM, and the interictal CGRP level may be used as a predictor for the response to GONB.

Indexed as

CGRPchronic migraineGONB

Identifiers

PMID35225886
PMCPMC8883968
OpenAlexW4210832881

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.